Crescent Biopharma (FRA:C68) Interest Expense: €-0.93 Mil (TTM As of Mar. 2026)


FRA:C68 Crescent Biopharma Inc FRA:C68
18 GF Score
Price €14.60
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Interest Expense?

Crescent Biopharma FRA:C68 18 Interest Expense is €-0.93 Mil as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Crescent Biopharma's interest expense for the three months ended in Mar. 2026 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.93 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Crescent Biopharma's Operating Income for the three months ended in Mar. 2026 was € -21.39 Mil. Crescent Biopharma's Interest Expense for the three months ended in Mar. 2026 was € 0.00 Mil. GuruFocus does not calculate Crescent Biopharma's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Crescent Biopharma  (FRA:C68) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Crescent Biopharma's Interest Expense for the three months ended in Mar. 2026 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-21.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.94 Mil.

Crescent Biopharma's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Crescent Biopharma's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Crescent Biopharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Interest Expense Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Interest Expense
0.00 -1.87

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial -1.03 -0.93 0.00 0.00 0.00
FRA:C68
18GF Score
Crescent Biopharma Inc FRA:C68
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.93 Mil mean?
Crescent Biopharma (FRA:C68) has a Interest Expense of €-0.93 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Crescent Biopharma and its competitors.
Is Crescent Biopharma's Interest Expense too high?
Crescent Biopharma's current Interest Expense is €-0.93 Mil. Overall, Crescent Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Interest Expense compare to KYTX and ZURA?
Crescent Biopharma's Interest Expense of €-0.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Interest Expense is €-0.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Interest Expense of €-0.93 Mil. The current Interest Expense is €-0.93 Mil. Crescent Biopharma's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Interest Expense is €-0.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
18GF Score

Get the complete analysis for FRA:C68

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price